Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||0.35%||463.19||2.7%||$534.62m|
|GILD||Gilead Sciences, Inc.||0.20%||64.75||1.0%||$502.19m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.76%||213.58||1.9%||$461.68m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.03%||150.06||2.0%||$329.21m|
|BNGO||BioNano Genomics, Inc.||8.67%||7.77||0.0%||$322.31m|
|CRSP||CRISPR Therapeutics AG||-0.90%||113.62||0.6%||$321.43m|
|EXAS||EXACT Sciences Corp.||-4.17%||116.57||18.4%||$244.18m|
|PACB||Pacific Biosciences of California, Inc.||-6.49%||27.37||7.2%||$176.05m|
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firmâ€™s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.